Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Chicago based virtual reality company reaches AIIMS, assisting in surgical planning and training
The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative
First Positive Study for KEYTRUDA in Adjuvant Stage IB-IIIA NSCLC
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Subscribe To Our Newsletter & Stay Updated
